First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments
Background Tumor-selective oncolytic viral vectors are promising anticancer therapeutics; however, challenges with dosing and potency in advanced/metastatic cancers have limited efficacy and usage. NG-350A is a next-generation blood-stable adenoviral vector engineered to express an agonist anti-clus...
| الحاوية / القاعدة: | Journal for ImmunoTherapy of Cancer |
|---|---|
| المؤلفون الرئيسيون: | , , , , , , , , |
| التنسيق: | مقال |
| اللغة: | الإنجليزية |
| منشور في: |
BMJ Publishing Group
2024-10-01
|
| الوصول للمادة أونلاين: | https://jitc.bmj.com/content/12/10/e010016.full |